Accessed: 01.05.2020
El 11 de marzo de 2020 la OMS (Organización Mundial de la salud) ha declarado el CORONAVIRUS - COVID 19 como una pandemia mundial después que el número de afectados fuera de China se haya multiplicado por 13 en dos semanas y el de los demás países se haya triplicado en e...ste mismo periodo
El 26/02/2020 se ha identificado el primer caso de coronavirus en Colombia de una paciente de 19 años proveniente de Milán, Italia y desde la fecha hasta hoy el número de casos se ha multiplicado exponencialmente en el país.
more
Global Level
COVID-19: Vulnerability to containment measures (21/04/2020)
COVID-19: Government Measures: Impact on Displaced Populations (16/04/2020)
COVID-19: Scenarios + Comparison table (10/04/2020)
COVID-19: Government Measures Report (26/03/2020)
Risk communication encompasses all the basics of health communication but differs in the need for speed and reliance on trust. At times of crisis, leaders are called on to provide a quick, sensitive and trustworthy response.
Recommendations for in-patient management of COVID-19 in adult patients
Version 10, November 2020.
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
Rev Saude Publica. 2022; 56: 22.
Published online 2022 Apr 11. doi: 10.11606/s1518-8787.2022056004040
Archives of Disease in Childhood 2021;106:238-240.
Africa Centers for Disease Control and Prevention (Africa CDC) is aware of the media releases of the preliminary results of a large randomized clinical trial conducted in the United Kingdom, which included dexamethasone, a corticosteroid, as one of the drugs used for the treatment of COVID-19 patien...ts. The investigators reported that administration of oral or injectable dexamethasone resulted in about one-third reduction in mortality among COVID-19 patientsi that required mechanical ventilation and about one-fifth for patients requiring oxygen.
more
就改进手卫生做法助力预防COVID-19病毒传播给会员国的建议
More than 100 countries across the world now have reported cases of COVID-19. People traveling to these countries or people who have travelled abroad might possibly have come in contact with people affected with COVID-19 during their stay or even while in transit at the airports. Within these countr...ies, few countries have reported very large number of cases and deaths putting passengers from these countries particularly at higher risk of infection.
more
The COVID-19 pandemic has affected everyone, including key populations at higher risk of HIV. And the gains made against other infectious diseases, including HIV, are at risk of being reversed as a result of disruptions caused by COVID-19. This is the background to a new report published by FHI 360,... in collaboration with UNAIDS, which gives advice on how to minimize the impacts of COVID-19 on key populations.
more
La presente establece los lineamientos y procedimientos para la vigilancia epidemiológica de COVID-19 en el país. Asimismo, los procedimientos, metodología e instrumentos para la vigilancia epidemiológica de COVID-19 en pacientes hospitalizados y las defunciones por COVID-19 en el país.
Resource Page for People At Risk For or With HIV and for Clinicians
Accessed: 02.05.2020
These interim IPC recommendations for health settings have been developed through the contributions of many individuals and institutions, such as the Centers for Disease Control-Kenya; ITECH; US Agency for International Development (USAID) Medicines, Technologies, and Pharmaceu...tical Services (MTaPS) Program; and WHO that are committed to ensuring that the transmission of COVID-19 to HCWs and the public within the health care setting is limited. The Ministry of Health (MOH) through the Directorate of Health Standards Quality Assurance and Regulations wishes to thank all the contributing authors led by the sub-committee on case management and IPC for the COVID-19 response for their expertise and time given to writing these guidelines.
more
The project aims to build trust around COVID-19 vaccines to ensure greater access to and uptake in the vaccines through establishing healthy information ecosystems to address mis- and disinformation and vaccine hesitancy in the Democratic Republic of Congo (DRC). The bulletins are in French.
COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important
to identify sources of variation so that policies can be tailored to different population groups. ...In this paper, we analyze the results from a survey designed and implemented in order to identify early adopters and
laggers in six big cities of Latin America. We find that trust in government and science, accurate knowledge about the value of vaccination and vaccine effects, perceived risk of getting sick, and being a student
increase the odds to get vaccinated. We also identify potential laggers as women and populations between 20 and 35 years old who are not students. We discuss specific strategies to promote vaccination among
these populations groups as well as more general strategies designed to gain trust. These findings are specific to the context of Latin America insofar as the underlying factors associated with the choice to be
vaccinated vary significantly by location and in relation to individual-level factors.
more
]. تختلف مخاطر التلوث COVID-19المادية في سياق جائحة مرض فيروس كـــورونـا المستجد [السطحي وانتقال العدوى باختلاف نوع الإعداد وحجم السكان الذين يترددون على كل مكان (مثل: م...افق الرعاية الصحية، والنقل العام، وغيرها من المرافق / أماكنيوضح هذا الدليل بالتفصيل المبادئ والإجراءات الأساسية للتطهير التي ينبغي اتباعها لتطهير البيئة العمل المزدحمة)، على الرغم من أن ا لعدم قدرتنا على تغطية كل موقف هنا، فإنه من الممكن ًمبادئ التطهير البيئي تظل كما هي. ونظرالقيام بتكييف هذا الدليل مع المواقف الفردية عند ظهورها. يركز هذا الدليل على كيفية تنفيذ عملية ، والذي تم )۱(ا وينبغي تقديمه كجزء من برنامج مخطط له ومحسوب المواردًإزالة التلوث البيئي عملي.]COVID-19دمجه بالكامل مع جهود الاستجابة الأخرى لمرض فيروس كـــورونـا المستج
more